Clearside Biomedical, Inc. (CLSD) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Xilio Therapeutics, Inc.

Clearside Biomedical, Inc.

Kinnate Biopharma, Inc.

Immunic, Inc.

Adicet Bio, Inc.

Clene, Inc.

Veru, Inc.

Outlook Therapeutics, Inc.

Eyenovia, Inc.

Ampio Pharmaceuticals, Inc.

Homology Medicines, Inc.

Why is Clearside Biomedical, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Operating profit has grown by an annual rate -19.36% of over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -6.57

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -95.77%, its profits have risen by 18.4%

Falling Participation by Institutional Investors

Institutional investors have decreased their stake by -1.11% over the previous quarter and collectively hold 16.67% of the company
These investors have better capability and resources to analyse fundamentals of companies than most retail investors

Below par performance in long term as well as near term

Along with generating -95.77% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Clearside Biomedical, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Clearside Biomedical, Inc.

-95.77%

-0.05

1173.94%

S&P 500

14.9%

0.77

19.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-19.47%

EBIT Growth (5y)

-19.36%

EBIT to Interest (avg)

-6.57

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.88

Sales to Capital Employed (avg)

0.33

Tax Ratio

2.38%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

16.67%

ROCE (avg)

ROE (avg)

0.20%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-0.06

EV to EBIT

-2.52

EV to EBITDA

-2.56

EV to Capital Employed

57.98

EV to Sales

17.42

PEG Ratio

Dividend Yield

ROCE (Latest)

-2296.20%

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

NET PROFIT(HY)

Higher at USD -10.47 MM

NET SALES(9M)

Higher at USD 3.02 MM

DEBT-EQUITY RATIO (HY)

Lowest at -101.6 %

-6What is not working for the Company

NET SALES(HY)

At USD 0.69 MM has Grown at -38.56%

RAW MATERIAL COST(Y)

Grown by 37.66% (YoY

CASH AND EQV(HY)

Lowest at USD 16.18 MM

Here's what is working for Clearside Biomedical, Inc.

Net Profit

Higher at USD -10.47 MM

than preceding 12 month period ended Sep 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Debt-Equity Ratio

Lowest at -101.6 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Here's what is not working for Clearside Biomedical, Inc.

Net Sales

At USD 0.69 MM has Grown at -38.56%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Cash and Eqv

Lowest at USD 16.18 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 37.66% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales